ClinicalTrials.gg
Not yet recruitingNCT07074236Updated Jul 24, 2025

Pharmacokinetics and Pharmacodynamics Study

A Phase 1 interventional study of QLC7401 injection and RBD7022 injection in Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Planned enrollment
47th of 53
48 · median 207
Started
2025
with 3 others
Phase 1
12 of 59
2 open now
Primary completion
2026-01
later than 4 of 16 live
Registered
54th of 59
by date

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 47th largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 in phase 1, reaches primary completion later than 4 of the 16 other live ones, and was the 54th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.

03

Conditions studied

  • Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females who are 18 to 65 years of age.
  • is within the range of 18\~28 kg/m2 (including the boundary value).
  • LDL-C is within the range of 1.8 mmol/L (70 mg/dl) and 4.1 mmol/L (158 mg/dl) (including the lower boundary value). TG is less than or equal to 4.5 mmol/L (400 mg/dl).
  • TC is less than 6.2 mmol/L (239 mg/dl).

Exclusion criteria

Exclusion Criteria:

  • Subjects with confirmed diabetes.
  • Subjects with severe active psychiatric illness or disorder.
  • is less than 90 ml/min.
  • is equal to or above the 2 fold of value or is equal to or above the 1.5 fold of upper limit of normal value.
  • Subjects administered prescription drugs 14 days before the first drug administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    QLC7401 injection

    Drug: QLC7401 injection

  • Experimental
    RBD7022 injection

    Drug: RBD7022 injection

Interventions

  • QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.

  • DrugRBD7022 injection

    RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration of QLC7401 and active metabolites.

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

  2. AUC

    Area under the concentration-time curve of QLC7401 and active metabolites.

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

  3. Tmax

    Time of maximum observed concentration of QLC7401 and active metabolites..

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

  4. t1/2

    Terminal elimination half-life of QLC7401 and active metabolites.

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

  5. CL/F

    Apparent total clearance of the drug from plasma after oral administration of QLC7401 and active metabolites.

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

  6. VZ/F

    Apparent volume of distribution after oral administration of QLC7401 and active metabolites.

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jan 2026, 6 months later.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 6 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 20, 2025
StartEst.
Jul 2025
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07074236
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jul 24, 2025

Study contacts

Yu Cao, doctorate
Contact
Caoyu1767@126.com
0532-82911767
Cheng qian Li, doctorate
Contact
Lichengqian5213@163.com
18661806523

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLC7401

Start the discussion